Alltrna received clearance to begin its first clinical trial, marking a step toward developing a reusable class of RNA therapeutics built around tRNA biology. The company’s approach is designed so that a single therapy platform could be adapted across diseases rather than treating each indication as a bespoke program. If successful, the model could reduce time and cost bottlenecks that often slow RNA therapy iteration from candidate creation to clinical manufacturing and early efficacy readouts. The clearance is notable as the industry continues to refine not just the biology of RNA drugs, but also the manufacturing and quality systems needed for consistent dosing across indications.